In mice, it has been demonstrated that sCD14 presents protective effects in inflammatory bowel disease and that a rise in the LBP/sCD14 ratio in both humans and mice is linked to an increase in plasma IL-6 [30]. This evidence concerns the gene IL6 and inflammatory bowel disease.